1466 — Baijin Life Science Holdings Income Statement
0.000.00%
Last trade - 00:00- HK$455.05m
- HK$523.80m
- HK$135.56m
Annual income statement for Baijin Life Science Holdings, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | R2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 43.3 | 62.6 | 86.9 | 53.7 | 136 |
| Cost of Revenue | |||||
| Gross Profit | -8.62 | 11 | 7.83 | 18.1 | 42 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 91 | 73.7 | 77.4 | 63.3 | 138 |
| Operating Profit | -47.6 | -11.1 | 9.49 | -9.58 | -2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -52.1 | -15.5 | 8.68 | -8.53 | -1.36 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -51.8 | -15.5 | 8.68 | -8.54 | -0.087 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -51.8 | -15.5 | 8.68 | -7.45 | -0.316 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -51.8 | -15.5 | 8.68 | -7.45 | -0.316 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.218 | -0.043 | 0.014 | -0.011 | 0.015 |